MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

The gross proceeds to MapLight from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions and offering expenses, were $296.3 million ...

(Reuters) -Shares of MapLight Therapeutics opened 11.8% above their offer price in their Nasdaq debut on Monday, giving the drug developer a $787 million valuation. The Redwood City, California-based ...

Sergey Brin’s name doesn’t appear in MapLight Therapeutics’ filings to go public, but the Google co-founder’s philanthropic ambitions could get a big boost from the biotech’s upcoming market ...

In addition to the shares sold in the initial public offering, MapLight announced a concurrent sale of 476,707 shares of common stock at the initial public offering price per share in a private ...

USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company to go public under a rarely used regulatory provision since the start of the U.S.